Basic Information
Loqtorzi
Regulatory Information
EMEA/H/C/006120
September 19, 2024
July 25, 2024
1
April 8, 2025
Company Information
Ireland
Ground Floor Two Dockland Central Guild Street I.F.S.C. Dublin 1 Co. Dublin D01 K2C5
TOPALLIANCE BIOSCIENCES EUROPE LIMITED
Drug Classification
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Loqtorzi, in combination with cisplatin and gemcitabine, is indicated for the first-line treatment of adult patients with recurrent, not amenable to surgery or radiotherapy, or metastatic nasopharyngeal carcinoma. Loqtorzi, in combination with cisplatin and paclitaxel, is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma.
Overview Summary
Loqtorzi is a cancer medicine used in adults to treat: - nasopharyngeal cancer (cancer of the nasopharynx, where the throat and nose connect) that is recurrent (has come back) and cannot be treated with surgery or radiotherapy or is metastatic (has spread to other parts of the body). It is used together with cisplatin and gemcitabine, other cancer medicines (also known as chemotherapy); - oesophageal squamous cell cancer, a type of cancer affecting the oesophagus (the passage from the mouth to the stomach). It is used when the cancer is advanced and cannot be removed by surgery or if it is recurrent or metastatic. It is used together with the chemotherapy medicines cisplatin and paclitaxel. Loqtorzi contains the active substance toripalimab.